New Delhi: India has decided to partially lift a ban on export of anti-malarial drug hydroxychloroquine, paving the way for its supply to the US and several other countries hit hard by the coronavirus pandemic.
Government officials said India would export hydroxychloroquine and paracetamol on a case-by-case basis to the countries which have already placed orders for them after meeting the domestic requirements.
The decision to partially lift the ban on hydroxychloroquine came to the fore hours after US President Donald Trump warned of retaliation if India does not heed to his request to supply the drug, cited by him as a viable therapeutic solution to fight coronavirus infection.
In a telephonic conversation with Prime Minister Narendra Modi on Sunday, Trump sought supply of hydroxychloroquine (HCQ) to the US.
“In view of the humanitarian aspects of the pandemic, it has been decided that India would licence paracetamol and HCQ in appropriate quantities to all our neighbouring countries who are dependent on our capabilities,” said Anurag Srivastava, Spokesperson in the Ministry of External Affairs.
“We will also be supplying these essential drugs to some nations which have been particularly badly affected by the pandemic,” he added, responding to queries on the issue.
On March 25, India banned export of hydroxychloroquine in the midst of views in some quarters that the drug could be used to fight COVID-19. India is the largest exporter of the drug.
It is learnt that high-ranking officials of India and the US were engaged over the issue of supply HCQ to the US by certain Indian companies following telephonic conversation between Modi and Trump and the decision to ease restrictions on export of the drug was result of a process.
The assessment in the government on Trump’s comment on “retaliation” is that his response was not pre-meditated and that it was an instantaneous reaction by the US President when put on the spot.
There was indication that the decision to lift the partial ban on the two drugs was taken at a high-level meeting on Monday night. Hydroxychloroquine is and inexpensive drug used to treat malaria.
India is the largest producer of the drug globally. Officials said India would export the drug on a case-by-case basis after meeting all the domestic requirements.
“India has always maintained that the international community must display strong solidarity and cooperation. This approach also guided our evacuation of nationals of other countries,” Srivastava said.
India is learnt to have received requests from at least 20 countries including its immediate neighbours Sri Lanka and Nepal for supply of hydroxychloroquine.
“Like any responsible government, our first obligation is to ensure that there are adequate stocks of medicines for the requirement of our own people,” the MEA spokesperson said. In order to ensure this, he explained, some “temporary steps” were taken to restrict exports of a number of pharmaceutical products.
He said a comprehensive assessment was carried out about possible requirements of various drugs under different scenarios.
He said the Directorate General of Foreign Trade (DGFT) has notified lifting of restrictions on 14 drugs on Monday.
The Indian Council of Medical Research (ICMR) has recommended the hydroxychloroquine for those involved in the care of suspected or confirmed cases of the coronavirus.
The Trump administration has already created a national strategic stockpile of 29 million doses of the malaria drug, anticipating that its test results on more than 1,500 COVID-19 patients in New York is yielding positive results. Global scientists, racing against time to find either a vaccine or a therapeutic cure to the virus, have begun testing hydroxychloroquine and chloroquine as options for potential COVID-19 treatments. (PTI)
